Delay in review of QT 1571(Novartis) for PAH - 20-Aug-2012

The FDA postponed a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review QT 1571 which is imatinib (Gleevec/Glivec in its cancer indication) from Novartis for Pulmonary Arterial Hypertension. Novartis has decided to withdraw the NDA to allow time to produce more information for the FDA

Related News

Related Cardiology Information

Related Cardiology Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013